Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$19.0M
Filings
101
Firms Hired
2
Active Period
2006–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: APOTEX CORP.
HR 5526/S. 1954, the Biosimilar Red Tape Elimination Act, provisions relating to deeming a biosimilar interchangeable with its reference product immediately upon approval.
Client expense: $730,000 · Firm income: —
Matched citations: HR 5526
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
Client expense: $730,000 · Firm income: —
Matched citations: HR 6485
HR 5526/S. 1954, the Biosimilar Red Tape Elimination Act, provisions relating to deeming a biosimilar interchangeable with its reference product immediately upon approval.
Client expense: $730,000 · Firm income: —
Matched citations: S. 1954
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
Client expense: $730,000 · Firm income: —
Matched citations: S. 43
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; HR 3269/S. 2276, the Eliminating Thickets to Increase Competition (ETHIC) Act, provisions relating to capping the number of patents that can be asserted against biosimilar and generic manufacturers to one per terminally disclaimed group; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
Client expense: $730,000 · Firm income: —
Matched citations: HR 3269
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; HR 3269/S. 2276, the Eliminating Thickets to Increase Competition (ETHIC) Act, provisions relating to capping the number of patents that can be asserted against biosimilar and generic manufacturers to one per terminally disclaimed group; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
Client expense: $730,000 · Firm income: —
Matched citations: HR 6485
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; HR 3269/S. 2276, the Eliminating Thickets to Increase Competition (ETHIC) Act, provisions relating to capping the number of patents that can be asserted against biosimilar and generic manufacturers to one per terminally disclaimed group; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
Client expense: $730,000 · Firm income: —
Matched citations: S. 2276
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; HR 3269/S. 2276, the Eliminating Thickets to Increase Competition (ETHIC) Act, provisions relating to capping the number of patents that can be asserted against biosimilar and generic manufacturers to one per terminally disclaimed group; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
Client expense: $730,000 · Firm income: —
Matched citations: S. 43
Protecting Investors’ Personally Identifiable Information Act
2025 · fourth_quarter · Firm: APOTEX CORP.
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.
Client expense: $260,000 · Firm income: —
Matched citations: HR 1483
Increasing Transparency in Generic Drug Applications Act
2025 · fourth_quarter · Firm: APOTEX CORP.
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.
Client expense: $260,000 · Firm income: —
Matched citations: S. 1302
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.
Client expense: $260,000 · Firm income: —
Matched citations: S. 43
Protecting Investors’ Personally Identifiable Information Act
2025 · third_quarter · Firm: APOTEX CORP.
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.
Client expense: $310,000 · Firm income: —
Matched citations: HR 1483
Increasing Transparency in Generic Drug Applications Act
2025 · third_quarter · Firm: APOTEX CORP.
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.
Client expense: $310,000 · Firm income: —
Matched citations: S. 1302
National Defense Authorization Act for Fiscal Year 2026
2025 · third_quarter · Firm: APOTEX CORP.
S. 2296, the National Defense Authorization Act for 2026, Section 878, Country-of-Origin Disclosure Requirements for Generic Drugs Purchased by the Department of Defense, provisions relating to prohibiting the Department of Defense from procuring for resale any generic drug unless the seller of such generic drug discloses the country the drug was manufactured in and the country of origin of all active pharmaceutical ingredients and key starting materials; Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs; and Federal policy relating to inspection of foreign generic drug manufacturing facilities.
Client expense: $310,000 · Firm income: —
Matched citations: S. 2296
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.
Client expense: $310,000 · Firm income: —
Matched citations: S. 43
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
2025 · first_quarter · Firm: APOTEX CORP.
America First Trade Policy Presidential Memorandum, provisions relating to a review of United States trade policies and agreements and the exemption of pharmaceuticals from tariffs; Executive Orders 14193, 14197, 14231, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals from such tariffs; Reciprocal Trade and Tariffs Presidential Memorandum, provisions relating to implementing reciprocal tariffs on countries that impose import duties on products from the United States and the exemption of pharmaceuticals from tariffs; and S.J.Res.37, provisions relating to terminating the national emergency declared on February 1, 2025, by the President in Executive Order 14193.
Client expense: $810,000 · Firm income: —
Matched citations: S.J.Res.37
Strengthening Immigration Procedures Act of 2024
2024 · fourth_quarter · Firm: APOTEX CORP.
S. 4683, the National Defense Authorization Act for Fiscal Year 2025, Section 887, Requirement to produce domestically produced generic drugs, provisions relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives to spur domestic manufacturing of generic drugs.
Client expense: $220,000 · Firm income: —
Matched citations: S. 4683
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Draft Senate Finance Committee drug shortage legislation (no bill number), provisions relating to Medicare reimbursement policies for generic drugs; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings; S. 5573, The Skinny Label Big Savings Act, provisions relating to creating a safe harbor for the use of the skinny labeling pathway for generic pharmaceuticals and biosimilars.
Client expense: $220,000 · Firm income: —
Matched citations: S. 5573
Strengthening Immigration Procedures Act of 2024
2024 · third_quarter · Firm: APOTEX CORP.
S. 4683, the National Defense Authorization Act for Fiscal Year 2025, Section 887, Requirement to produce domestically produced generic drugs, provisions relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; Federal policy relating to providing tax incentives to spur domestic manufacturing of generic drugs; and Federal policy related to Administration for Strategic Preparedness and Response initiatives to strengthen domestic pharmaceutical manufacturing capabilities.
Client expense: $160,000 · Firm income: —
Matched citations: S. 4683
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities; Federal policy relating to requiring the military to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically; Draft Senate Finance Committee drug shortage legislation, provisions relating to Medicare reimbursement policies for generic drugs; and Federal policy relating to rebating impacts on access to biosimilars
Client expense: $160,000 · Firm income: —
Matched citations: S. 2510
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.
Client expense: $140,000 · Firm income: —
Matched citations: S. 2510
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.
Client expense: $530,000 · Firm income: —
Matched citations: S. 2510
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.
Client expense: $530,000 · Firm income: —
Matched citations: S. 2510
National Defense Authorization Act for Fiscal Year 2024
2023 · third_quarter · Firm: APOTEX CORP.
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; S. Amendment 532 to S. 2226, the National Defense Authorization Act, provisions relating to reviewing domestic biopharmaceutical manufacturing capabilities; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.
Client expense: $120,000 · Firm income: —
Matched citations: S. 2226
Pandemic and All-Hazards Preparedness and Response Act
2023 · third_quarter · Firm: APOTEX CORP.
Federal policy relating to formulary placement of generic drugs and biosimilars; and S. 2333, the Pandemic and All-Hazards Preparedness Act, Title V, Section 501, Improving Notification Procedures In Case of Increased Demand for Critical Drugs, provisions relating to reporting the discontinuance of manufacturing drugs and active pharmaceutical ingredients.
Client expense: $120,000 · Firm income: —
Matched citations: S. 2333
Source: Senate LDA